Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI) [Phase 3]

View source ↗

Summary

Phase 3 trial update on ustekinumab maintenance therapy for Crohn's disease in patients with moderately to severely active disease. Results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Inflammatory Bowel Disease
• Ulcerative Colitis

Drugs mentioned

• Stelara (ustekinumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Crohn's Disease, Colitis | Phase 3 | Status: COMPLETED | Results posted: 2017-02-23